论文信息 - Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer. - 字舞流文

Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.

A. Barrett | G. Westbury | P. Cawte | R. Mould | K. Hellmann | K. Newton | S. E. James | M. Bakowski | V. Dalley | E. Macdonald | J. Sloggem

[1] M. Bakowski. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. , 1976, Cancer treatment reviews.

[2] J. Bertino,et al. The role of chemotherapy in the management of cancer of the head and neck: A review , 1975, Cancer.

[3] S. Carter,et al. The integration of chemotherapy into a combined modality approach to cancer therapy , 1975 .

[4] G. Murkin,et al. Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors , 1974, Cancer.

[5] D. Goffinet,et al. Clinical use of radiation sensitizing agents. , 1974, Cancer treatment reviews.

[6] G. Ramírez,et al. Combined therapy in advanced head and neck cancer: a randomized study. , 1972, The American journal of roentgenology, radium therapy, and nuclear medicine.

[7] I. Bross,et al. Sequential Medical Plans. , 1952 .